These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

66 related articles for article (PubMed ID: 6184273)

  • 21. Acute ventricular fibrillation and death during infusion of 4'-(9-acridinylamino)methanesulfon-m-anisidide (AMSA).
    Von Hoff DD; Elson D; Polk G; Coltman C
    Cancer Treat Rep; 1980; 64(2-3):356-8. PubMed ID: 6931630
    [No Abstract]   [Full Text] [Related]  

  • 22. Phase II study of amsacrine in metastatic renal cell carcinoma: a Cancer and Leukemia Group B study.
    Amrein PC; Coleman M; Richards F; Poulin RF; Berkowitz I; Kennedy BJ; Green M; Herschkopf R; Rafla S
    Cancer Treat Rep; 1983 Nov; 67(11):1043-4. PubMed ID: 6688967
    [No Abstract]   [Full Text] [Related]  

  • 23. [Treatment of acute myeloid leukemia].
    Obrecht JP
    Folia Haematol Int Mag Klin Morphol Blutforsch; 1984; 111(2):190-200. PubMed ID: 6208102
    [No Abstract]   [Full Text] [Related]  

  • 24. m-AMSA: phase II trial in advanced lymphoma and leukemia.
    Case DC
    Am J Clin Oncol; 1984 Aug; 7(4):357-60. PubMed ID: 6588746
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Phase II study of 4'-(9-acridinylamino)methanesulfon-m-anisidide (NSC 249992) in children with acute leukemia and lymphoma.
    Tan CT; Hancock C; Steinherz PG; Steinherz LJ; Sorell M; Chan KW; Mondora A; Miller DR
    Cancer Res; 1982 Apr; 42(4):1579-81. PubMed ID: 6895864
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Venous protection of acute leukemia treatment with amsacrine].
    Ma XJ; Xiang YM; Hong J
    Zhonghua Hu Li Za Zhi; 1996 Sep; 31(9):506-7. PubMed ID: 9295513
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Phase II trial of amsacrine in patients with hepatoma: a Cancer and Leukemia Group B study.
    Amrein PC; Richards F; Coleman M; Poulin RF; Holland JF; Weinberg V; Perry M
    Cancer Treat Rep; 1984 Jun; 68(6):923-4. PubMed ID: 6329510
    [No Abstract]   [Full Text] [Related]  

  • 28. Acridinyl anisidide (m-AMSA) therapy in 11 patients with refractory acute leukemia.
    Naparstek E; Shinar E; Polliack A
    Isr J Med Sci; 1984 Feb; 20(2):118-22. PubMed ID: 6546740
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Acute tumor lysis in T-cell leukemia induced by amsacrine.
    Vogler WR; Morris JG; Winton EF
    Arch Intern Med; 1983 Jan; 143(1):165-6. PubMed ID: 6600389
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Acute myocardial necrosis during administration of amsacrine.
    Lindpaintner K; Lindpaintner LS; Wentworth M; Burns CP
    Cancer; 1986 Apr; 57(7):1284-6. PubMed ID: 3753891
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Distribution of 159 cases of acute non-lymphoblastic leukaemia (ANLL) according to the FAB classification, and prognostic correlations (author's transl)].
    Sanz MA; Amigo V; Gomis F; Pérez Sirvent ML; Besalduch J; Rafecas J; Martinez J; Marty ML
    Sangre (Barc); 1981; 26(5-C):1019-25. PubMed ID: 7323923
    [No Abstract]   [Full Text] [Related]  

  • 32. Hyperdiploid clone in a patient with acute non-lymphocytic leukaemia (ANLL), previously treated with radio and chemotherapy for Hodgkin's lymphoma (HL).
    Zaccaria A; Rosti G; Testoni N; Tura S
    Haematologica; 1983; 68(2):233-8. PubMed ID: 6407917
    [No Abstract]   [Full Text] [Related]  

  • 33. Pilot study of 5-azacytidine (5-AZA) and carboplatin (CBDCA) in patients with relapsed/refractory leukemia.
    Kritz AD; Raptis G; Menendez-Botet C; Maslak P; Jakubowski A
    Am J Hematol; 1996 Feb; 51(2):117-21. PubMed ID: 8579051
    [TBL] [Abstract][Full Text] [Related]  

  • 34. m-AMSA: an exciting new drug in the National Cancer Institute Drug Development Program.
    Weiss RB; Charles LM; Macdonald JS
    Cancer Clin Trials; 1980; 3(3):203-9. PubMed ID: 7002337
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Amsacrine administration: a precautionary note.
    Engelking C; Sullivan P; Agoliati G; Arlin ZA
    Cancer Chemother Pharmacol; 1984; 13(2):150. PubMed ID: 6547883
    [No Abstract]   [Full Text] [Related]  

  • 36. Induction of complete remission in a patient with acute myeloid leukemia refractory to high-dose chemotherapy through treatment with 5-azacytidine.
    Kuendgen A; Gräf T; Zohren F; Hildebrandt B; Hünerlitürkoglu A; Gattermann N; Haas R; Kobbe G
    Leuk Res; 2007 Mar; 31(3):407-9. PubMed ID: 16890286
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Clinical activity of m-Amsa and the combination of m-Amsa with cytosine arabinoside].
    Weil M; Auclerc MF; Schaison G; Auclerc G; Daubrisson A; Degos L; Caro J; Marty M; Jacquillat GI
    Nouv Presse Med; 1982 Oct; 11(39):2911-4. PubMed ID: 6755389
    [TBL] [Abstract][Full Text] [Related]  

  • 38. AMSA-induced seizures in patients with hypokalemia.
    Mittelman A; Arlin ZA
    Cancer Treat Rep; 1983 Jan; 67(1):102-3. PubMed ID: 6688555
    [No Abstract]   [Full Text] [Related]  

  • 39. Trial of AMSA in acute leukemia.
    Dupont JC; Garay GE; Scaghone C; Pavlovsky S; Woodley PV
    Cancer Treat Rep; 1982 Jul; 66(7):1596-7. PubMed ID: 7046933
    [No Abstract]   [Full Text] [Related]  

  • 40. Treatment of metastatic ovarian carcinoma with amsacrine: a cancer and leukemia group B phase II study.
    Amrein PC; Coleman M; Richards F; Bhardwaj S; Kennedy BJ; Haurani FI; Frelick RW; Pastmantier MW; Herschkopf R
    Cancer Treat Rep; 1984 Nov; 68(11):1397-8. PubMed ID: 6548660
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 4.